Study Details

Back to Search Results

A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) using Multidetector Computed Tomography (MDCT) compared to Single Photon Emission Computed Tomography (SPECT)

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT01334918

Astellas Study ID

The unique identification code given by the study sponsor.

3606-CL-2001

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Heart Disease

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

45 years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Apr 2011 - Jul 2012

Masking

None (Open Label)

Enrollment number

124

A Phase 2, Open-Label, Randomized, Cross-Over Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging by Multidetector Computed Tomography (MDCT) and Single Photon Emission Computed Tomography (SPECT)

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) using Multidetector Computed Tomography (MDCT) compared to Single Photon Emission Computed Tomography (SPECT)? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Oregon Health and Science University

Portland, United States, 97239

Maine Research Associates

Auburn, United States, 04210

Heart Center Research LLC

Huntsville, United States, 35611

Henry Ford Health System

Detroit, United States, 48202

Michigan Heart, PC

Ypsilanti, United States, 48197

Santa Rosa Cardiology Medical Group, Inc.

Santa Rosa, United States, 95405

Midwest Cardiology Associates, P.C.

Overland Park, United States, 66029

Brigham and Women's Hospital

Boston, United States, 02115

Alfieri Cardiology, P.A.

Newark, United States, 19713

Berkshire Medical Center

Pittsfield, United States, 01201

Baptist Hospital of Miami

Miami, United States, 33176

Harbor UCLA Medical Center

Torrance, United States, 90502

Sutter Roseville Medical Center

Roseville, United States, 95661

Cardiovascular Research Center of South Florida

Miami, United States, 33173

Medical University of South Carolina

Charleston, United States, 29401

Massachusetts General Hospital

Boston, United States, 02114

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo